BiotechTube

Elotuzumab (BMS-901608; HuLuc63)

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoldering Multiple Myeloma

Conditions

Smoldering Multiple Myeloma

Trial Timeline

Dec 28, 2011 → Jan 17, 2017

NCT ID
NCT01441973

About Elotuzumab (BMS-901608; HuLuc63)

Elotuzumab (BMS-901608; HuLuc63) is a phase 2 stage product being developed by AbbVie for Smoldering Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT01441973. Target conditions include Smoldering Multiple Myeloma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01441973Phase 2Completed

Competing Products

13 competing products in Smoldering Multiple Myeloma

See all competitors
ProductCompanyStageHype Score
BHQ880NovartisPhase 2
52
carfilzomib + Lenalidomide + Dexamethasone + MelphalanAmgenPhase 2
51
DenosumabAmgenPhase 2
51
Carfilzomib + Lenalidomide + Daratumumab + DexamethasoneAmgenPhase 2
51
ElranatamabPfizerPhase 2
51
Nivolumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
51
Elotuzumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
51
Dexamethasone + Iberdomide HydrochlorideBristol Myers SquibbPhase 2
51
LinvoseltamabRegeneron PharmaceuticalsPhase 2
51
Linvoseltamab + DaratumumabRegeneron PharmaceuticalsPhase 3
76
SelinexorKaryopharm TherapeuticsPhase 2
44
IPH2101Innate PharmaPhase 2
44
PD-L1 peptideIO BiotechPhase 2
44

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85